Occult hepatitis B virus infection in chronic hemodialysis patients in Korea
Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 50 Irwon-dong, Gangnam-Gu, 135-710, Seoul, South Korea. Hepato-gastroenterology
(Impact Factor: 0.93).
Occult HBV infection that is serum HBsAg negative but HBV DNA positive is thought to be a contributing factor to ongoing HBV transmission within hemodialysis units. In the present study, the prevalence of occult HBV infection was investigated in patients on chronic hemodialysis in Korea, an endemic region for HBV.
Eighty-three patients undergoing maintenance hemodialysis at Samsung Medical Center, Seoul, South Korea were included. Serum samples were obtained from all patients. Testing for HBsAg, anti-HBs and anti-HBc was performed by an electrochemiluminescence immunoassay. HBV DNA was detected by the nested PCR method.
Among the 83 patients, 4 (4.8%) were HBsAg positive and HBV DNA positive. The remaining 79 patients were confirmed HBsAg-negative/HBV DNA-negative. Thus, the prevalence of occult HBV infection was 0%. All of the HBsAg-positive patients were anti-HBs-negative/anti-HBc-positive. Of 79 HBsAg-negative patients, 58 (73.4%) were anti-HBs positive and 52 (65.8%) were anti-HBc positive.
The present study showed that the prevalence of occult HBV infection in chronic hemodialysis patients at our center in Korea was not increased compared to the rates of low endemic regions. Furthermore, occult HBV infection was not a contributing factor in HBV transmission in the hemodialysis unit studied.
Available from: e-med.co.il
Gastroentérologie Clinique et Biologique 06/2009; 33(6-7). DOI:10.1016/j.gcb.2009.03.002 · 1.14 Impact Factor
Available from: Ali Reza Samarbasf-Zadeh
[Show abstract] [Hide abstract]
ABSTRACT: Introduction and objective: Hepatitis B virus (HBV) is a member of Hepadnaviridae and a major causative agent of chronic and acute hepatitis, liver cirrhosis and hepatocellular carcinoma. Genotype determination of HBV is based on PCR-RFLP and sequencing of genome of the virus. The genotype formation is mainly due to mutations of HBV precore, S, and YMDD (tyrosine-methionine-aspartate-aspartate motif in the C domain of the HBV DNA polymerase gene) genome area. Moreover, some of the mutant HBV remains undetectable by serological tests (occult hepatitis). Since the genotypes of HBV and occult hepatitis B has not been studied in our area, this study was conducted to determine both occult hepatitis B infection and genotypes among hemodialysis patients.Materials and methods: Two hundred and fifty hemodialysis patients were selected in this study. The sera of the patients were collected and the extracted DNA was used as template of PCR to amplify a 479bp fragment of the viral genome. The PCR products were digested by Ava2 and Mbo1 restriction enzymes. Based on RFLP patterns, the genotypes were determined. The HBV markers including; HBV surface antigen (HBsAg), hepatitis Bc antibody (HBcIgG), hepatitis B virus e antigen (HBeAg) and hepatitis B virus e antibody (HBeAb) were carried out for all the patients by ELISA test.Results: Fifty (20%) out of 250 sera showed positive HBV by PCR. Out of the 50 positive cases for HBV, 46(92%) belonged to genotype D2 and 2(4%) cases of them were B6 genotype. Ten cases were positive for HBV by PCR test but negative by ELISA test (4% occult hepatitis). Conclusion: Prevalence of HBV infection was high among the dialysis patients (20%), and occult hepatitis B was 4% in these patients. The dominant genotype of HBV was D2 (92%) followed by genotypes B6 (4%) in hemodialysis patients.
Jundishapur Journal of Microbiology 01/2011; 4(2). · 0.39 Impact Factor
World Journal of Gastroenterology 01/2011; 17(12):1538. DOI:10.3748/wjg.v17.i12.1538 · 2.37 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.